Volume 87 Issue 10 | p. 15 | Concentrates
Issue Date: March 9, 2009

BMS Links With Japanese Firms

Department: Business

Bristol-Myers Squibb is collaborating with the Japanese companies Nissan Chemical Industries and Teijin Pharma to develop Nissan’s NTC-801 outside Japan. Teijin already has Japanese rights. A selective inhibitor of the acetylcholine-activated potassium ion channel, NTC-801 is currently in Phase I development in Japan for treating a form of arrhythmia. BMS will pay $40 million up front and potentially make milestone payments of up to $170 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society